Inari Medical Appoints Pulmonologist Dr. Victor F. Tapson as VP of Medical Affairs
September 21 2021 - 8:00AM
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device
company focused on developing products to treat and transform the
lives of patients suffering from venous diseases, today announced
that the company has appointed Victor F. Tapson, M.D. as VP of
Medical Affairs.
Dr. Tapson has devoted his medical career to patient care,
research, and teaching in pulmonary hypertension and pulmonary
embolism. He has authored more than 200 peer-reviewed manuscripts
and was involved in the development of the American Thoracic
Society’s clinical practice guidelines for the diagnosis of venous
thromboembolism. “I am thrilled to be joining Inari Medical on its
mission to revolutionize the treatment of pulmonary embolism and
deep venous thrombosis,” said Dr. Tapson. Prior to Inari, Dr.
Tapson was in practice at Cedars-Sinai Medical Center in Los
Angeles, CA where he started the first Pulmonary Embolism Response
Team (PERT) on the west coast. Dr. Tapson has been an officer and
board member of the PERT Consortium, serving as its first elected
President.
Prior to his time at Cedars, Dr. Tapson spent over two decades
at Duke University Medical Center where he was a professor of
medicine and focused on lung transplantation, pulmonary
hypertension, and pulmonary embolism clinical research. He
co-founded the Duke Lung Transplant Program, Duke Chronic
Thromboembolic Pulmonary Hypertension (CTEPH) Program, and Duke
Pulmonary Vascular Disease Center, serving as its Director for 20
years.
Dr. Tapson is a graduate of Drexel University School of Medicine
in Philadelphia, PA. He completed his medical and pulmonology
training at Duke University Medical Center and Boston
University/Boston City Hospital. He is board-certified in
internal medicine and pulmonary disease, and is fellowship-trained
in pulmonary and critical care.
“In order to establish a new gold standard for the treatment of
VTE, not only is clinical data required but so is a change in
systems of care,” said Dr. Thomas Tu, Chief Medical Officer of
Inari. “As a thought leader in the VTE space and pioneer of the
PERT concept, Vic innately understands this and is uniquely
qualified to enable Inari to execute.”
About Inari Medical, Inc.Inari Medical, Inc. is
a medical device company focused on developing products to treat
and transform the lives of patients suffering from venous diseases.
Inari has developed two minimally invasive, novel catheter-based
mechanical thrombectomy devices that are designed to remove large
clots from large vessels and eliminate the need for thrombolytic
drugs. The company purpose-built its products for the specific
characteristics of the venous system and the treatment of the two
distinct manifestations of venous thromboembolism, or VTE: deep
vein thrombosis and pulmonary embolism. The ClotTriever system is
510(k)-cleared by FDA and CE Mark approved for the treatment of
deep vein thrombosis. The FlowTriever system is 510(k)-cleared by
FDA and CE Mark approved for the treatment of pulmonary embolism
and clot in transit in the right atrium.
Investor Contact:Westwicke PartnersCaroline
CornerPhone +1-415-202-5678 caroline.corner@westwicke.com
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Sep 2023 to Sep 2024